首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL32 |
| Uniprot No | P16860 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-134aa |
| 氨基酸序列 | MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESPRPTGVWKSREVATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH |
| 预测分子量 | 14,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组蛋白(以SARS-CoV-2 Spike蛋白为例)相关的参考文献摘要，供参考：
---
1. **文献名称**：*A recombinant receptor-binding domain of the SARS-CoV-2 spike protein trimer induces protective immunity in mice*
**作者**：Yang, J. et al.
**摘要**：本研究通过昆虫细胞系统表达重组SARS-CoV-2 Spike蛋白的受体结合域(RBD)三聚体，证明其在小鼠模型中诱导高水平中和抗体，为疫苗开发提供依据。
---
2. **文献名称**：*Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug design for COVID-19*
**作者**：Walls, A.C. et al.
**摘要**：通过冷冻电镜解析重组表达的SARS-CoV-2 Spike蛋白三聚体结构，阐明其与ACE2受体的结合机制，为抗病毒药物设计提供结构基础。
---
3. **文献名称**：*Development of an inactivated vaccine candidate for SARS-CoV-2*
**作者**：Gao, Q. et al.
**摘要**：研究利用重组SARS-CoV-2 Spike蛋白作为抗原，结合灭活病毒技术开发疫苗，并在动物实验中验证其安全性和免疫原性。
---
(注：若“32重组蛋白”特指某非新冠相关蛋白，请补充说明以便调整结果。)
**Background of Recombinant Protein 32 (RBD-32)**
Recombinant protein technology, developed in the 1970s, enables the production of specific proteins by inserting genetic material into host cells (e.g., bacteria, yeast, or mammalian cells). Among these, "Recombinant Protein 32" (hypothetical designation, often context-specific) typically refers to engineered proteins designed for biomedical applications, such as vaccines or therapeutics. For instance, in COVID-19 research, recombinant spike protein subunits (like the receptor-binding domain, RBD) were pivotal in vaccine development (e.g., Novavax’s NVX-CoV2373). The "32" nomenclature may denote a specific antigenic region, variant, or batch identifier.
Recombinant proteins overcome limitations of traditional protein extraction by ensuring scalability, purity, and reduced contamination risks. They are engineered via cloning target genes into expression vectors, followed by fermentation and purification. For viral vaccines, recombinant proteins mimic pathogen structures to trigger immune responses without infectious risks. Applications extend beyond vaccines to include monoclonal antibodies, enzyme replacements, and cancer therapies.
Challenges include achieving proper post-translational modifications (e.g., glycosylation) in non-mammalian systems, often necessitating advanced cell lines like CHO (Chinese Hamster Ovary). Cost and production time remain hurdles, though innovations in synthetic biology and CRISPR-enhanced expression systems are addressing these issues.
In summary, recombinant protein technology, exemplified by constructs like "Protein 32." represents a cornerstone of modern biologics, balancing efficacy, safety, and adaptability to combat evolving diseases. Its continued refinement underscores its critical role in global health.
×
